Talazoparib

Drug Profile

Talazoparib

Alternative Names: BMN-673; LT 006673; LT-00673; LT-673; MDV-3800; Talazoparib tosylate

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator LEAD Therapeutics
  • Developer BioMarin Pharmaceutical; Medivation; National Cancer Institute (USA); St. Jude Childrens Research Hospital; University of California at San Francisco; University of Maryland Greenbaum Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Fluorobenzenes; Phthalazines; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia
  • Phase I Ewing's sarcoma; Pancreatic cancer; Small cell lung cancer
  • Preclinical Glioblastoma; Non-small cell lung cancer
  • Discontinued Haematological malignancies

Most Recent Events

  • 05 Apr 2017 Pharmacodynamics data from a preclinical trial in Ovarian cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Mar 2017 Medivation initiates enrolment in a phase I trial for Solid tumours (Late-stage disease) in Hungary and Moldova (NCT03077607)
  • 01 Jan 2017 Phase-I clinical trials in Solid tumours (Late-stage disease) in Moldova (PO) (NCT03077607)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top